Create an Account

Rare and Orphan Diseases

Episodes 0-0 of 0

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Adjuvant Nivolumab Alone or in Combination with Ipilimumab Versus Placebo in Stage IV Melanoma with No Evidence of Disease: Overall Survival Results of IMMUNED, a Randomized, Double-Blind Multi-Center Phase 2p DeCOG Trial
      Adjuvant Nivolumab Alone or in Combination with Ipilimumab Versus Placebo in Stage IV Melanoma with No Evidence of Disease: Overall Survival Results of IMMUNED, a Randomized, Double-Blind Multi-Center Phase 2p DeCOG Trial

      Learn More

      Adjuvant Nivolumab Alone or in Combination with Ipilimumab Versus Placebo in Stage IV Melanoma with No Evidence of Disease: Overall Survival Results of IMMUNED, a Randomized, Double-Blind Multi-Center Phase 2p DeCOG Trial
      UP NEXT...
      Adjuvant Nivolumab Alone or in Combination with Ipilimumab Versus Placebo in Stage IV Melanoma with No Evidence of Disease: Overall Survival Results of IMMUNED, a Randomized, Double-Blind Multi-Center Phase 2p DeCOG Trial
      CME

      Welcome to the new
      Global Oncology Academy website.

      NEW FEATURES:

      • Check out all the new educational programs we have added.New educational programs
      • Now mobile-friendly and easier to navigate.Now mobile-friendly
      • A learner profile that stores your history/CME certificates.Track your credits
      Register

      We’re glad to see you’re enjoying Global Oncology Academy…
      but how about a more personalized experience?

      Register for free
      You are now leaving Global Oncology Academy and going to a site run by another organization.

      Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.